74,000 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by Ilmarinen Mutual Pension Insurance Co

Ilmarinen Mutual Pension Insurance Co acquired a new stake in Exact Sciences Co. (NASDAQ:EXAS) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 74,000 shares of the medical research company’s stock, valued at approximately $4,158,000.

A number of other institutional investors have also recently bought and sold shares of EXAS. Geode Capital Management LLC raised its position in shares of Exact Sciences by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 3,122,798 shares of the medical research company’s stock valued at $175,165,000 after acquiring an additional 16,828 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Exact Sciences by 3.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,330,939 shares of the medical research company’s stock worth $74,785,000 after purchasing an additional 38,849 shares during the period. Groupama Asset Managment boosted its position in shares of Exact Sciences by 0.3% during the fourth quarter. Groupama Asset Managment now owns 1,209,146 shares of the medical research company’s stock worth $67,942,000 after purchasing an additional 4,194 shares in the last quarter. Norges Bank acquired a new position in shares of Exact Sciences in the 4th quarter valued at $50,625,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Exact Sciences by 63.6% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 549,262 shares of the medical research company’s stock valued at $30,863,000 after buying an additional 213,557 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Trading Down 3.9 %

Shares of Exact Sciences stock opened at $42.55 on Friday. Exact Sciences Co. has a 1 year low of $40.62 and a 1 year high of $74.44. The company has a market capitalization of $7.90 billion, a price-to-earnings ratio of -7.64 and a beta of 1.14. The business has a fifty day simple moving average of $48.64 and a two-hundred day simple moving average of $56.98. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93.

Exact Sciences (NASDAQ:EXAS) last announced its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.23. The business had revenue of $713.42 million during the quarter, compared to the consensus estimate of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. Research analysts forecast that Exact Sciences Co. will post -0.58 EPS for the current year.

Analysts Set New Price Targets

EXAS has been the subject of a number of research analyst reports. Benchmark reissued a “buy” rating and issued a $65.00 target price on shares of Exact Sciences in a research note on Monday, January 13th. William Blair reiterated an “outperform” rating on shares of Exact Sciences in a report on Thursday, February 20th. Barclays cut their target price on Exact Sciences from $70.00 to $65.00 and set an “overweight” rating on the stock in a research note on Thursday, February 20th. Guggenheim set a $60.00 price objective on shares of Exact Sciences and gave the company a “buy” rating in a report on Friday, March 28th. Finally, Bank of America reduced their target price on shares of Exact Sciences from $72.00 to $65.00 and set a “buy” rating for the company in a report on Thursday, February 20th. Two analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $70.26.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.